

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
		IDS Filed	October 14, 2009

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	5,023,252	6/11/91	Hsieh
	5,034,506	7/23/91	Summerton et al.
	5,225,347	7/6/93	Goldberg et al.
	5,580,859	12/3/96	Felgner et al.
	5,719,262	2/17/98	Buchardt et al.
	5,766,855	6/16/98	Buchardt et al.
	5,834,279	11/10/98	Rubin et al.
	5,998,383	12/7/99	Wright et al.
	6,121,000	9/19/00	Wright et al.
	6,593,305	7/15/03	Wright et al.
	7,405,205	7/29/08	Wright et al.
	2006/0241070	10/26/2006	Wright

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	0 383 190	8/22/90	EP	
	94/21661	9/29/94	WO	
	95/02069	1/19/95	WO	
	98/00532	1/8/98	WO	
	98/05769	2/12/98	WO	

EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.</p>	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
(37 C.F.R. § 1.98(b))		IDS Filed	October 14, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	99/02673	1/21/99	WO	
	00/47733	8/17/00	WO	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)				
	Abaza et al., FASEB J., 15(4):A555, 2001 (Abstract only).			
	Agrawal et al., "Reconstitution of Signal Transduction from the Membrane to the Nucleus in a Baculovirus Expression System: Activation of Raf-1 Leads to Hypermodification of c-jun, and c-fos via Multiple Pathways." Oncogene 11(3):427-38, 1995.			
	Agrawal, "Antisense oligonucleotides: towards clinical trials" TIBTECH 14:376-387 1996.			
	Akhter et al., "Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)" Nucleic Acids Res 19(20):5551-9, 1991.			
	Aksoy et al., "Combined interferon alpha with levamisole in patients with metastatic renal cell carcinoma" Int Urol Nephrol 33(3):457-9, 2001.			
	Amara et al., "Phorbol Ester Modulation of a Novel Cytoplasmic Protein Binding Activity at the 3'-Untranslated Region of Mammalian Ribonucleotide Reductase R2 mRNA and Role in Message Stability" J Biol Chem 269:6709-6715, 1994.			
	Amara et al., "Defining a novel cis-element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA. cis-trans-interactions and message stability" J Biol Chem 271(33):20126-31, 1996.			
	Amara et al., "Defining a novel cis element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA: role in transforming growth factor-beta 1 induced mRNA stabilization" Nucleic Acids Res 23(9):1461-7, 1995.			
	Atzpodien et al., "Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma" Cancer 95(5):1045-50, 2002.			
	Auer et al., "Bcl-2 antisense (Genasense™) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells" Blood 98(11): 808a, 2001 (Abstract only).			
	Barker, R.H. Jr. et al., "Inhibition of Plasmodium falciparum malaria using antisense oligodeoxynucleotides" Proc Natl Acad Sci USA 93(1):514-518, 1996.			
	Bitonti et al., "Response of human colon and prostate tumor xenografts to (E)-2'-deoxy-2'-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase" Anticancer Res 15(4): 1179-1182, 1995.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
(37 C.F.R. § 1.98(b))		IDS Filed	October 14, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Bitonti et al., "Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase" Cancer Res 54(6):1485-1490, 1994.
	Bjorklund et al., "S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs" Biochemistry 29:5452-5458, 1990.
	Bjorklund et al., "Structure and promoter characterization of the gene encoding the large subunit (R1 protein) of mouse ribonucleotide reductase" Proc Natl Acad Sci USA 90:11322-11326, 1993.
	Blaesse, "Gene therapy for cancer" Scientific American 276(6):111-115, 1997.
	Bleumer et al. "Immunotherapy for renal cell carcinoma" Eur Urol 44(1):65-75, 2003.
	Blosmanis et al., "Sensitivity to melphalan as a function of transport activity and proliferative rate in BALB/c 3T3 fibroblasts" Cancer Res 47:1273-1277, 1987.
	Bradley et al., "Experimental metastasis in nude mice of NIH 3T3 cells containing various ras genes" Proc Natl Acad Sci USA 83:5277-5281, 1986.
	Branch, "A good antisense molecule is hard to find" Trends Biochem Sci 23(2):45-50, 1998.
	Calabretta et al., "Antisense strategies in the treatment of leukemias" Semin. Oncol. 23:78-87, 1996.
	Caras et al., "Cloned mouse ribonucleotide reductase subunit M1 cDNA reveals amino acid sequence homology with Escherichia coli and Herpesvirus ribonucleotide reductase" Biol Chem., 260:7015-7022, 1985.
	Chadee et al., "Increased phosphorylation of histone H1 in mouse fibroblasts transformed with oncogenes or constitutively active mitogen-activated protein kinase kinase" J Biol Chem 270:20098-20105, 1995.
	Chakrabarti, et al., "Cloning and characterization of subunit genes of ribonucleotide reductase, a cell-cycle-regulated enzyme, from Plasmodium falciparum" Proc Natl Acad Sci USA 90:12020-12024, 1993.
	Chan et al., "Phosphorylation of ribonucleotide reductase R2 protein: in vivo and in vitro evidence of a role for p34cdc2 and CDK2 protein kinases" Biochemistry 32:12835-12840, 1993.
	Chaudhuri et al., "Cdn sequence of the small subunit of the hamster ribonucleotide reductase" Biochimica et Biophysica Acta 1117:117-121, 1992.
	Chen et al., "Defining a novel ribonucleotide reductase r1 mRNA cis element that binds to a unique cytoplasmic trans-acting protein" Nucleic Acids Res 22:4796-4797, 1994.
	Chen et al., "Mammalian ribonucleotide reductase R1 mRNA stability under normal and phorbol ester stimulating conditions: involvement of a cis-trans interaction at the 3' untranslated region" EMBO J 12:3977-3986, 1993.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
(37 C.F.R. § 1.98(b))		IDS Filed	October 14, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Chilambar and Wereley, "Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis" Cancer Research 55:4361-4366, 1995.
	Chiu et al., "Inhibition of mammalian ribonucleotide reductase by cis-diamminedichloroplatinum(II)" Biochemistry and Cell Biology 70(12): 1332-1338, 1992.
	Cho-Chung, "Antisense DNAs as targeted therapeutics for cancer: no longer a dream" Curr Opin Investig Drugs 3(6):934-9, 2002.
	Choy et al., "Transient elevation of ribonucleotide reductase activity, M2 mRNA and M2 protein in BALB/c 3T3 fibroblasts in the presence of 12-O-tetradecanoylphorbol-13-acetate" Biochem Biophys Res Commun 162:1417-1424, 1989.
	Choy et al., "Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations" Cancer Res 48:2029-2035, 1988.
	Cole et al., "Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line" Science 258:1650-1654, 1992.
	Cory et al., "Structural aspects of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of L1210 cell growth and ribonucleotide reductase activity" Adv Enzyme Regul 33:129-140, 1993.
	Crooke, "Progress in antisense therapeutics" Hematol Pathol 9(2):59-72, 1995.
	Davis et al., "Purification, characterization, and localization of subunit interaction area of recombinant mouse ribonucleotide reductase r1 subunit" J. Biol. Chem 269:23171-23176, 1994.
	Dutcher et al., "Preliminary report of a phase 1 study of intravenous (IV) CCI-779 given in combination with interferon- α (IFN) to patients with advanced renal cell carcinoma (RCC)" Proc Am Soc Clin Oncol 22:213, 2003 (Abstract 854).
	Duxbury et al., "RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine" Oncogene 23:1539-1548, 2004.
	Edwards et al., "Transcriptional regulation of two serum-induced RNAs in mouse fibroblasts: equivalence of one species to B2 repetitive elements" Mol Cell Biol 5:3280-3288, 1985.
	Eriksson et al., "Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis" J Biol Chem 259:11695-11700, 1984.
	Fabianowska and Majewska, "2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy" Acta Pol Pharm 53(4):231-239, 1996.
	Fan et al., "Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1835
(37 C.F.R. § 1.98(b))		IDS Filed	October 14, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	activated oncogenes to determine transformation and malignant potential" Proc Natl Acad Sci USA. 93(24):14036-40 1996.
	Fan et al., "A link between ferritin gene expression and ribonucleotide reductase R2 protein, as demonstrated by retroviral vector mediated stable expression of R2 cDNA" FEBS Lett 382:145-148, 1996.
	Fan et al., "The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments" Proc Natl Acad Sci 94:13181-13186, 1997.
	Funk et al., "A transcriptionally active DNA-binding site for human p53 protein complexes" Mol Cell Biol 12(6):2866-2871, 1992.
	Gandhi et al., "Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions" Blood 87(1):256-264, 1996.
	Gewirtz, "Oligodeoxynucleotide-based therapeutics for human leukemias" Stem Cells 11:96-103, 1993.
	Gewirtz et al., "Facilitating oligonucleotide delivery: helping antisense deliver on its promise" Proc Natl Acad Sci USA 93:3161-3163, 1996.
	Giacca et al., "Synergistic Antiviral Action of Ribonucleotide Reductase Inhibitors and 3'-azido-3'-deoxythymidine on HIV Type 1 Infection In Vitro" AIDS Res Hum Retroviruses 12(8):677-682, 1996.
	Gilboa, E., "Immunotherapy of cancer with genetically modified tumor vaccines" Semin Oncol 23(1):101-107, 1996.
	Goldberg et al., "Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma" Cancer, 95(6):1220-7, 2002.
	Good and Nielsen, "Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA" Proc Natl Acad Sci USA. 95(5):2073-6, 1998.
	Gura, "Systems for identifying new drugs are often faulty" Science 278:1041-1042, 1997.
	Hanania et al., "Recent advances in the application of gene therapy to human disease" Am J Med 99:537-552, 1995.
	Hards and Wright, "N-carbamoyloxymurea-resistant Chinese hamster ovary cells with elevated levels of ribonucleotide reductase activity" J Cell Physiol 106:309-319, 1981.
	Holmlund, "Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development" Ann N Y Acad Sci 1002:244-51, 2003.
	Huang et al., "Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability" Cancer Res. 57(21):4876-81, 1997.
	Hurta et al., "Early induction of ribonucleotide reductase gene expression by transforming growth factor beta
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
(37 C.F.R. § 1.98(b))		IDS Filed	October 14, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	1 in malignant H-ras transformed cell lines" J Biol Chem 266(35):24097-24100, 1991.
	Hurta and Wright, "Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent" J Biol Chem 267:7066-7071, 1992.
	Hurta and Wright, "Alterations in the cyclic AMP signal transduction pathway regulating ribonucleotide reductase gene expression in malignant H-ras transformed cell lines." J Cell Physiol 158:187-197, 1994.
	Hurta and Wright, "Malignant transformation by H-ras results in aberrant regulation of ribonucleotide reductase gene expression by transforming growth factor-beta 1" J Cell Biochem 57:543-556, 1995.
	Jelinek et al., "RAS and RAF-1 form a signalling complex with MEK-1 but not MEK-2" Mol Cell Biol 14:8212-8218, 1994.
	Jensen et al., "Identification of genes expressed in premalignant breast disease by microscopy-directed cloning" Proc Nat Acad Sci USA 91:9257-9261, 1994.
	Kohn, "Regulatory genes and drug sensitivity" J Natl Cancer Inst 88(18):1255-6, 1996.
	Koong et al., "Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2)" Cancer Res 54(20):5273-9, 1994.
	Kuschak et al., "c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene" Oncogene 21:909-920, 2002.
	Leevers et al., "Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane" Nature 369(6479):411-4, 1994.
	Lefebvre-d'Heillecourt et al., "Immunomodulation by cytokine antisense oligonucleotides" Eur Cytokine Netw 6(1):7-19, 1995.
	Lenormand et al., "Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway" J Biol Chem 271(26):15762-8, 1996.
	Lewis et al., "Ribonucleotide reductase from wild type and hydroxyurea-resistant chinese hamster ovary cells" J Cell Physiol 97(1):87-97, 1978.
	Lewis et al., "Assay of ribonucleotide reduction in nucleotide-permeable hamster cells" J Cell Physiol 94(3):287-98, 1978.
	Mann et al., "Ribonucleotide reductase M2 subunit in cellular proliferation, quiescence, and differentiation" J Cancer Res 48:5151-5156, 1988.
	McClarty et al., "Elevated expression of M1 and M2 components and drug-induced posttranscriptional modulation of ribonucleotide reductase in a hydroxyurea-resistant mouse cell line" Biochemistry, 26: 8004-8011, 1987.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
(37 C.F.R. § 1.98(b))		IDS Filed	October 14, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	McClarty et al., "Molecular mechanisms responsible for the drug-induced posttranscriptional modulation of ribonucleotide reductase levels in a hydroxyurea-resistant mouse L cell line" <i>Biochemistry</i> , 27:7524-7531, 1988.
	McClarty et al., "Increased ferritin gene expression is associated with increased ribonucleotide reductase gene expression and the establishment of hydroxyurea resistance in mammalian cells" <i>J Biol Chem</i> 265:7539-7547, 1990.
	Morgan and Kastan, "p53 and ATM: cell cycle, cell death, and cancer" <i>Adv. Cancer Res.</i> , 71:1-25, 1997.
	Motzer et al., "p53 and ATM: cell cycle, cell death, and cancer" <i>J Clin Oncology</i> 20(1):289-296, 2002.
	Negrier et al., "Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie" <i>Ann Oncol</i> 13(9):1460-8, 2002.
	Negrier et al., "Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer" <i>J Clin Oncol</i> 15;18(24):4009-4015, 2000.
	Parker et al., "Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie" <i>Nucleic Acids Research</i> , 19(13):3741, 1991.
	Pavlick et al., "Novel therapeutic agents under investigation for malignant melanoma" <i>Exp Opin Inves Drugs</i> 12:1545-1558, 2003.
	Piepmeler et al., "In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor" <i>Cancer Res</i> 56(2):359-361, 1996.
	Potsch et al., "p-Alkoxyphenols, a new class of inhibitors of mammalian R2 ribonucleotide reductase: possible candidates for antineoplastic drugs" <i>Mol Pharmacol</i> 45(4):792-796, 1994.
	Price et al., "Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer" <i>Proc Natl Acad Sci USA</i> 84:156-160, 1987.
	Pyrhonen et al., "Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer" <i>J Clin Oncol</i> 17(9):2859-67, 1999.
	Qui et al., "An essential role for Rac in Ras transformation" <i>Nature</i> , 374:457-459, 1995.
	Recchia et al., "Interleukin-2 (IL-2) and 13-cis retinoic acid (RA) prolong disease-free and overall survival in recurrent ovarian cancer (ROC)" <i>Proc. 2004 European Society of Medical Oncology Congress, Vienna, Abstr. #491P</i> .
	Reichard, "From RNA to DNA, why so many ribonucleotide reductases?" <i>Science</i> 260:1773-1777, 1993.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No.	50120/008001 10/585,772
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
(37 C.F.R. § 1.96(b))		IDS Filed	October 14, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Rojanasakul, "Antisense oligonucleotide therapeutics: drug delivery and targeting" Advanced Drug Delivery Reviews 18:115-131, 1996.
	Rosolen et al., "Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line" Cancer Res 50:6316-6322, 1990.
	Roy et al., "Inhibition of ribonucleotide reductase by nitric oxide derived from thionitrites: reversible modifications of both subunits" Biochemistry 34:5411-5418, 1995.
	Saeki et al., "Immunohistochemical detection of ribonucleotide reductase in human breast tumors" Int. J. Oncol. 6:523-529, 1995.
	Salem et al., "High level expression of the large subunit of mouse ribonucleotide reductase in a baculovirus system" FEBS Lett 323(1-2):93-5, 1993.
	Santarossa et al., "Ribonucleotide reductase inhibition in the treatment of advanced prostate cancer: an experimental approach with hydroxyurea and gallium nitrate in 20 patients" Eur J Cancer 31a(10):1718, 1995.
	Scanlon et al., "Oligonucleotide-mediated modulation of mammalian gene expression" FASEB J 9:1288-1296, 1995.
	Seheult et al., Abstracts of the General Meeting of the American Society for Microbiology, 102:191, 2002.
	Shaw et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum" Nucleic Acids Res 19:747-750, 1991.
	Slabaugh et al., "Vaccinia Virus Ribonucleotide Reductase Expression and Isolation of the Recombinant Large Subunit" J Biol Chem 268(24):17803-17810, 1993.
	Standart et al., "Maternal mRNA from clam oocytes can be specifically unmasked in vitro by antisense RNA complementary to the 3'-untranslated region" Genes Dev 4(12A):2157-2168, 1990.
	Stubbe, "Protein radical involvement in biological catalysis?" Ann Rev Biochem 58:257-285, 1989.
	Sun et al., "Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy" Gene Therapy 8:638-645, 2001.
	Szekeres et al., "Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase" Cancer Chemother Pharmacol 34:63-66, 1994.
	Takeda and Weber, "Role of Ribonucleotide Reductase in Expression of Neoplastic Program" Life Science, 28:1007-1014, 1981.
	Theilander et al., "Ribonucleotide reductase from calf thymus. Separation of the enzyme into two nonidentical subunits, proteins M1 and M2" J Biol Chem 255:7426-7432, 1980.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
		IDS Filed	October 14, 2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Thelander et al., "Subunit M2 of mammalian ribonucleotide reductase. Characterization of a homogeneous protein isolated from M2-overproducing mouse cells." J Biol Chem., 260:2737-2741, 1985.
	Thelander and Berg, "Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase" Mol Cell Biol 6(10):3433-3442, 1986.
	Thelander and Thelander, "Molecular cloning and expression of the functional gene encoding the M2 subunit of mouse ribonucleotide reductase: a new dominant marker gene" EMBO J 8(9):2475-2479, 1989.
	Tonin et al., "Chromosomal assignment of amplified genes in hydroxyurea-resistant hamster cells" Cytogenet Cell Genet 45:102-108, 1987.
	Tourani et al., "Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design—the Subcutaneous Administration Propeukin Program Cooperative Group" J Clin Oncol 21(21):3987-3994, 2003.
	Van Herpen et al., "Immunotherapy with Interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party" Br J Cancer 82(4):772-776, 2000.
	Wagner, "Gene inhibition using antisense oligodeoxynucleotides" Nature 372:333-335, 1994.
	Wagner et al., "Potent and selective inhibition of gene expression by an antisense heptanucleotide" Nature Biotechnology, 14:840-844, 1996.
	Weber, "Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture" Cancer Res 43:3466-3492, 1983.
	Weckbecker et al., "Effects of N-hydroxy-N'-aminoguanidine derivatives on ribonucleotide reductase activity, nucleic acid synthesis, clonogenicity, and cell cycle of L1210 cells" Cancer Res 47(4): 975-978, 1987.
	Wright and Anazodo, "Altered expression of ribonucleotide reductase and role of M2 gene amplification in hydroxyurea-resistant hamster, mouse, rat, and human cell lines" Somat Cell Mol Genet 13:155-165, 1987.
	Wright et al., "Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis" Biochem Cell Biol 68:1364-1371, 1990.
	Wright et al., "Hydroxyurea and related compounds" Antimetabolites and Cytotoxic Analogs 1:15-27, 1989.
	Wright and Anazodo, "Altered mammalian ribonucleoside diphosphate reductase from mutant cell lines" The Cancer Journal, 8(4):185-189, 1995.
	Wright, "Antisense molecules and their potential for the treatment of cancer and AIDS" Encyl Pharmacol Therapeut 128:89-111, 1989.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No.	50120/008001 10/585,772
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
(37 C.F.R. § 1.98(b))		IDS Filed	October 14, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Yakubov et al., "Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?" Proc Natl Acad Sci USA 86:6454-6458, 1989.
	GenBank Entry NM_001034, "Homo sapiens ribonucleotide reductase M2 polypeptide (RRM2), mRNA." (20-DEC-2003), National Center for Biotechnology Information, Bethesda, MD.
	GenBank Entry NM_009104, "Mus musculus ribonucleotide reductase M2 (Rrm2), mRNA." (20-DEC-2003), National Center for Biotechnology Information, Bethesda, MD.
	GenBank Entry X68127, "M. auratus mRNA for ribonucleotide reductase M2 subunit." (30-JUN-1993), National Center for Biotechnology Information, Bethesda, MD.
	Press Release dated April 14, 1999 – Lorus Therapeutics Signs Agreement to Acquire GeneSense Technologies Inc.
	Press Release dated November 16, 1999 – Lorus Therapeutics Files IND Application Following Positive Preclinical Results of Anti-Cancer Drug GTI 2040.
	Press Release dated November 22, 1999 – Lorus Therapeutics Announces Dramatic Anti-Tumor Results For GTI 2040.
	Press Release dated December 7, 1999 – Lorus Therapeutics Announces FDA Approval To Begin Clinical Trials Of Anti-Cancer Drug GTI 2040.
	Press Release dated December 20, 1999 – Lorus Therapeutics Reports Results Of International Scientific Study.
	Press Release dated January 26, 2000 – Lorus Therapeutics Receives Issued United States Patent For Invention Of Key Anti-Cancer Drugs.
	Press Release dated February 7, 2000 – Lorus Therapeutics' Anti-Cancer Drug NC 381 Inhibits The Spread Of Human Melanoma Tumor Cells In Mice.
	Press Release dated February 28, 2000 – Lorus Therapeutics' Lead Anticancer Drugs Reduce Tumor Growth In Mouse Models With Human Prostate Cancer Cells.
	Press Release dated March 30, 2000 – Findings on Lorus Therapeutics' Lead Anti-Cancer Drug Presented At Annual Meeting Of American Association for Cancer Research.
	Press Release dated May 23, 2000 – Progress in Lorus Therapeutics' GTI-2040 Phase I/II Clinical Trial.
	Press Release dated October 17, 2000 – Lorus Announces Intention To Enter Phase II Clinical Trials For GTI-2040 With Strategic Supply Alliance.
	Press Release dated October 19, 2000 – Lorus Therapeutics Presents Anticancer Drug GTI-2040 at International Oncology Meeting In Greece.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
		IDS Filed	October 14, 2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Press Release dated March 5, 2001 – Lorus Therapeutics To Present Research of Lead Antisense Drug at Industry Conference.
	Press Release dated March 26, 2001 – Lorus Therapeutics To Present Three Anti-Cancer Drugs at Annual Meeting Of The American Association For Cancer Research.
	Press Release dated May 2, 2001 – Lorus Therapeutics Inc. Announces Two New Members To Its Board Of Directors.
	Press Release dated May 9, 2001 – Lorus Therapeutics Inc. To Present Clinical Results For Lead Antisense AntiCancer Drug at ASCO.
	Press Release dated July 18, 2001 – Lorus Therapeutics Reports Year-End Results.
	Press Release dated July 20, 2001 – Lorus Therapeutics Reports Year-End Results.
	Press Release dated July 24, 2001 – Lorus Therapeutics' GTI-2040 Prolongs Survival Rate in Mice Models With Lymphoma In Pre-Clinical Testing.
	Press Release dated October 17, 2001 – Lorus Therapeutics Reports First Quarter Results.
	Press Release dated October 30, 2001 – Lorus Advances Antisense Clinical Program For Renal Cell Carcinoma.
	Press Release dated February 21, 2002 – Scientific Publication Describes Oncogene Interaction With Lorus Anticancer Target.
	Press Release dated June 18, 2002 – Lorus Therapeutics And U.S. National Cancer Institute To Collaborate On The Conduct Of Multiple Phase II Clinical Trials With Lorus' GTI-2040.
	Press Release dated October 15, 2002 – Lorus Therapeutics Reports First Quarter Results.
	Press Release dated January 17, 2003 – Lorus Therapeutics Reports Second Quarter Results.
	Press Release dated February 5, 2003 – Lorus Announces Expansion of Renal Cell Carcinoma Clinical Trial To Major Oncology Centers In The United States.
	Press Release dated March 10, 2003 – Lorus Therapeutics Allowed United States Patent to Protect Key Antisense Anticancer Target.
	The Ottawa Citizen, June 19, 2002 – "Lorus Therapeutics shares jump after new trials approved."
	Copy of Office Action, mailed November 13, 2007, for U.S. Patent Application No. 10/545,152.
	Copy of Office Action, mailed May 15, 2008, for U.S. Patent Application No. 10/545,152.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p>		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
(37 C.F.R. § 1.98(b))		IDS Filed	October 14, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Copy of Office Action, mailed February 20, 2009, for U.S. Patent Application No. 10/545,152.
	Copy of Office Action, mailed October 14, 1999, for U.S. Patent Application No. 9/249,247.
	Copy of Office Action, mailed July 6, 2000, for U.S. Patent Application No. 9/249,247.
	Copy of Office Action, mailed March 27, 2001, for U.S. Patent Application No. 9/249,247.
	Copy of Office Action, mailed June 5, 2002, for U.S. Patent Application No. 9/249,247.
	Copy of Notice of Allowance, mailed January 14, 2003 for U.S. Patent Application No. 9/249,247.
	Copy of Office Action, mailed March 28, 2006, for U.S. Patent No. 10/447,136.
	Copy of Office Action, mailed September 11, 2006, for U.S. Patent No. 10/447,136.
	Copy of Office Action, mailed January 5, 2007, for U.S. Patent No. 10/447,136.
	Copy of Office Action, mailed July 9, 2007, for U.S. Patent No. 10/447,136.
	Copy of Notice of Allowance, mailed February 6, 2008, for U.S. Patent No. 10/447,136.

EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.</p>	